Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

Skip Navigation

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers ICONIC

Brief Summary

Type:
Urologic / Genitourinary - Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03866382

Study #:
STUDY00144561

Start Date:
Oct 17, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03866382

View Complete Trial Details & Eligibility at ClinicalTrials.gov